Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C

Journal of Clinical Gastroenterology

Volumn 35, Issue 1, 2002, Pages 89-92

  Willson, Richard A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic hepatitis C; Interferon alfa ribavirin therapy; Nephrotoxicity

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; DRUG MIXTURE; FEMALE; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; NEPHROTIC SYNDROME; RIBAVIRIN;

EID: 0036083811     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200207000-00019     Document Type: Article

References (34)

1. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients
2. Clinical toxicity of interferons in cancer patients: A review
3. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for myosis fungoides
4. Nephrotic syndrome during treatment with interferon
5. Acute renal failure during therapy with recombinant human gamma interferon
6. Interferon-induced reversible acute renal failure with nephrotic syndrome
7. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma
8. Acute renal failure and nephrotic syndrome with alpha interferon therapy
9. Therapeutic efficacy of recombinant interferon-alpha in polycythaemica vera
10. Acute renal failure with α-interferon therapy: A case report
11. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: Report on two patients
12. Renal toxicity in long-term alpha interferon treatment in a patient with myeloma
13. Membranoproliferative glomerulonephritis in a patient treated with interferon-alpha for human immunodeficiency virus infection
14. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B
15. Membranoproliferative glomerulonephritis in a patient with Hairy cell leukemia treated with alpha II interferon
16. Nephrotic range of proteinuria and interferon therapy
17. Acute renal failure during interferon treatment
18. Unusual glomerular lesion in a patient receiving long-term interferon alfa
19. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon
20. Side effects of alpha interferon in chronic hepatitis C
21. Adverse events associated with interferon alfa therapy in patients with chronic viral hepatitis
22. Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
23. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
24. Recombinant interferon alfa 2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C
25. Safety of combination interferon alfa-2b/Ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients
26. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
27. Focal segmental glomerulosclerosis among patients infected with hepatitis C virus
28. The many masks of focal segmental glomerulosclerosis
29. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C infection after interferon therapy
30. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
31. Mitochondrial toxic effects and ribavirin
32. Extrahepatic manifestations of chronic viral hepatitis
33. Risk of kidney failure associated with the use of acetaminophen, aspirin and nonsteroidal antiinflammatory drugs
34. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition